How many insider trades does FilingIQ track for LYRA?

FilingIQ tracks 107 Form 4 insider transactions for LYRA (Lyra Therapeutics, Inc.), covering filings from May 1, 2020 onwards. 2 of those were filed in the last 90 days.

Are LYRA insiders net buyers or net sellers?

Across the full Form 4 history for LYRA, 34 transactions (32%) were open-market purchases and 27 (25%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does LYRA insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is LYRA in?

Lyra Therapeutics, Inc. (LYRA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.57M.

LYRA insider trading

NasdaqCM Healthcare

Lyra Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

107

Last 90 days

Buys / sells

32% / 25%

Market cap

$2.57M

About Lyra Therapeutics, Inc.

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Company website: lyratherapeutics.com

LYRA insider activity at a glance

FilingIQ has scored 107 insider transactions for LYRA since May 1, 2020. The most recent filing in our index is dated Apr 1, 2026.

Across the full history, 34 open-market purchases and 27 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on LYRA insider trades is 59.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live LYRA trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding LYRA

Samsara BioCapital, LLC

$3.57M · 0.7% of AUM

Frequently asked

How many insider trades does FilingIQ track for LYRA?: FilingIQ tracks 107 Form 4 insider transactions for LYRA (Lyra Therapeutics, Inc.), covering filings from May 1, 2020 onwards. 2 of those were filed in the last 90 days.
Are LYRA insiders net buyers or net sellers?: Across the full Form 4 history for LYRA, 34 transactions (32%) were open-market purchases and 27 (25%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does LYRA insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is LYRA in?: Lyra Therapeutics, Inc. (LYRA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.57M.

Methodology & sources

Every LYRA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.